Nebulized versus intravenous morphine titration for the initial treatment of severe acute pain in the emergency department: study protocol for a multicenter, prospective randomized and controlled trial, CLIN-AEROMORPH.
Acute Pain
/ drug therapy
Adolescent
Adult
Aged
Analgesics, Opioid
/ administration & dosage
Emergency Service, Hospital
Humans
Middle Aged
Morphine
/ administration & dosage
Nebulizers and Vaporizers
Outcome Assessment, Health Care
Prospective Studies
Randomized Controlled Trials as Topic
Single-Blind Method
Young Adult
Analgesia
Morphine
Nebulized
Pain
Randomised controlled trial
Single blind
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
11 Apr 2019
11 Apr 2019
Historique:
received:
26
12
2018
accepted:
25
03
2019
entrez:
13
4
2019
pubmed:
13
4
2019
medline:
20
8
2019
Statut:
epublish
Résumé
Intravenous morphine titration (IVMT) is the French gold standard for opioid treatment in the emergency department (ED). Nebulized morphine titration (NMT) may represent an alternative without venous access, but it has not been adequately studied in adults. We test the hypothesis that NMT is at least as effective as IVMT to initially manage severe acute pain in the ED. We designed a multicenter (10 French EDs), single-blind, randomized and controlled trial. Adults between 18 and 75 years with visual analog scale (VAS) ≥ 70/100 or numeric rating scale (NRS) ≥ 7/10 will be enrolled. We will randomize 850 patients into two groups to compare two routes of MT as long as VAS > 30 or NRS > 3. In group A (425), patients will receive an initial NMT for 5-25 min associated with titration of an intravenously (IV) administered placebo of physiologic serum (PS). In group B (425), patients will receive IVMT plus nebulized PS placebo. NMT is defined as a minimum of 1 and a maximum of 3 5-min nebulized boluses of 10 mg or 15 mg (weight ≥ 60 kg), at 10-min fixed intervals. IVMT is defined as a minimum of 1 and a maximum of 6 boluses of 2 mg or 3 mg (weight ≥ 60 kg), at 5-min fixed intervals. Nebulized placebo titration will be performed every 10 min. IV titration of PS will be performed every 5 min. In both groups, after 25 min, if VAS > 30/100 or NRS > 3/10, routine IVMT will be continued until pain relief. Pain severity, vital signs, bronchospasm, and Ramsay score will be recorded every 5 min. The primary outcome is the rate of relief obtained 1 h from the start of drug administration. Complete pain relief in both groups will be compared with a non-inferiority design. Secondary outcomes are pain relief at 30 min (the end of NMT) and at 2 h and median pain relief. We will compare final doses, and study the feasibility and tolerance of NMT (protocol deviations, respiratory or hemodynamic depression, sedation, and minor vegetative side effects). Co-analgesia will be recorded. Discharge criteria from the ED and hospital are defined. This trial is the first multicenter randomized and controlled NMT protocol for severe pain in the ED using the titration concept. We propose an original approach of combined titration with an endpoint at 1 h and a non-inferiority design. ClinicalTrials.gov, NCT03257319 . Registered on 22 August 2017.
Sections du résumé
BACKGROUND
BACKGROUND
Intravenous morphine titration (IVMT) is the French gold standard for opioid treatment in the emergency department (ED). Nebulized morphine titration (NMT) may represent an alternative without venous access, but it has not been adequately studied in adults. We test the hypothesis that NMT is at least as effective as IVMT to initially manage severe acute pain in the ED.
METHODS/DESIGN
METHODS
We designed a multicenter (10 French EDs), single-blind, randomized and controlled trial. Adults between 18 and 75 years with visual analog scale (VAS) ≥ 70/100 or numeric rating scale (NRS) ≥ 7/10 will be enrolled. We will randomize 850 patients into two groups to compare two routes of MT as long as VAS > 30 or NRS > 3. In group A (425), patients will receive an initial NMT for 5-25 min associated with titration of an intravenously (IV) administered placebo of physiologic serum (PS). In group B (425), patients will receive IVMT plus nebulized PS placebo. NMT is defined as a minimum of 1 and a maximum of 3 5-min nebulized boluses of 10 mg or 15 mg (weight ≥ 60 kg), at 10-min fixed intervals. IVMT is defined as a minimum of 1 and a maximum of 6 boluses of 2 mg or 3 mg (weight ≥ 60 kg), at 5-min fixed intervals. Nebulized placebo titration will be performed every 10 min. IV titration of PS will be performed every 5 min. In both groups, after 25 min, if VAS > 30/100 or NRS > 3/10, routine IVMT will be continued until pain relief. Pain severity, vital signs, bronchospasm, and Ramsay score will be recorded every 5 min. The primary outcome is the rate of relief obtained 1 h from the start of drug administration. Complete pain relief in both groups will be compared with a non-inferiority design. Secondary outcomes are pain relief at 30 min (the end of NMT) and at 2 h and median pain relief. We will compare final doses, and study the feasibility and tolerance of NMT (protocol deviations, respiratory or hemodynamic depression, sedation, and minor vegetative side effects). Co-analgesia will be recorded. Discharge criteria from the ED and hospital are defined.
DISCUSSION
CONCLUSIONS
This trial is the first multicenter randomized and controlled NMT protocol for severe pain in the ED using the titration concept. We propose an original approach of combined titration with an endpoint at 1 h and a non-inferiority design.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov, NCT03257319 . Registered on 22 August 2017.
Identifiants
pubmed: 30975187
doi: 10.1186/s13063-019-3326-3
pii: 10.1186/s13063-019-3326-3
pmc: PMC6458825
doi:
Substances chimiques
Analgesics, Opioid
0
Morphine
76I7G6D29C
Banques de données
ClinicalTrials.gov
['NCT03257319']
Types de publication
Clinical Trial Protocol
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Pagination
209Subventions
Organisme : PHRCN
ID : 760780239
Références
Am J Emerg Med. 2015 Nov;33(11):1557-61
pubmed: 26143313
Eur J Anaesthesiol. 2001 Mar;18(3):159-65
pubmed: 11298174
J Pain Symptom Manage. 2002 Jan;23(1):7-9
pubmed: 11779662
Br J Anaesth. 2007 Jan;98(1):124-30
pubmed: 17065166
J Pain Symptom Manage. 2006 Aug;32(2):101-2; author reply 102-3
pubmed: 16877173
Clin Pharmacokinet. 1997 Sep;33(3):225-44
pubmed: 9314613
Life Sci. 2000;66(23):2221-31
pubmed: 10855942
Anesthesiology. 2001 Dec;95(6):1329-38
pubmed: 11748388
Anesthesiology. 2003 Jun;98(6):1415-21
pubmed: 12766651
Eur J Clin Pharmacol. 2007 Aug;63(8):761-7
pubmed: 17541571
Ann Emerg Med. 2005 Oct;46(4):362-7
pubmed: 16187470
Br Med J. 1974 Jun 22;2(5920):656-9
pubmed: 4835444
Am J Emerg Med. 1989 Nov;7(6):620-3
pubmed: 2803357
J Pain Symptom Manage. 2005 Jun;29(6):613-8
pubmed: 15963870
Br J Anaesth. 2002 Nov;89(5):697-701
pubmed: 12393765
Rev Infirm. 2002 Mar;(79):41-3
pubmed: 11979677
Anesthesiology. 2000 Sep;93(3):619-28
pubmed: 10969293
Br J Clin Pharmacol. 1996 Mar;41(3):250-2
pubmed: 8866928
Br J Clin Pharmacol. 2002 Apr;53(4):347-54
pubmed: 11966664
Chest. 2004 Feb;125(2):363-5
pubmed: 14769709
Emerg Med Australas. 2009 Jun;21(3):203-9
pubmed: 19527280
Br J Anaesth. 1988 Aug;61(2):228-30
pubmed: 3415896
Am J Emerg Med. 2008 Jul;26(6):676-82
pubmed: 18606320
Ann Fr Anesth Reanim. 2004 Oct;23(10):973-85
pubmed: 15501627
Clin Pharmacol Ther. 1997 Dec;62(6):596-609
pubmed: 9433388
Am J Hosp Palliat Care. 1995 Sep-Oct;12(5):7
pubmed: 7546980
Anesth Analg. 2012 Nov;115(5):1071-7
pubmed: 22984155
J Opioid Manag. 2009 Jan-Feb;5(1):23-6
pubmed: 19344045
Ann Fr Anesth Reanim. 2010 Jun;29(6):415-8
pubmed: 20537851
Ann Emerg Med. 2004 Apr;43(4):494-503
pubmed: 15039693
Am J Hematol. 2004 Jun;76(2):190-1
pubmed: 15164390
J Pain Res. 2017 Dec 12;10:2781-2788
pubmed: 29263692
Ann Pharmacother. 2016 Oct;50(10):882-91
pubmed: 27413071
J Pain Symptom Manage. 2005 May;29(5 Suppl):S90-103
pubmed: 15907650
J Trauma. 2005 Aug;59(2):383-8; discussion 389-90
pubmed: 16294079